European Monitoring Centre for Drugs and Drug Addiction. (2020) Risk assessment report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006. Luxembourg: Publications Office of the European Union.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Isotonitazene)
- Published Version
1MB |
This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020. On the basis of the Risk Assessment Report, on 2 September 2020, the Commission decided that isotonitazene should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA. Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with Commission Delegated Directive (EU) 2020/1687 by 3 June 2021.
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > Europe
VA Geographic area > Europe > United Kingdom
Repository Staff Only: item control page